Breast cancer is composed of multiple molecular subtypes such asER, PR andHER2, while triple-negative breast cancer (TNBC) lacks ER, PR and HER2 expression, leading to distinct morphologies, treatment responses and clinical outcomes [41]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.